 |
|
Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Youjin Chang, Seon Ye Kim, Yun Jung Choi, Kwang Sup So, Jin Kyung Rho, Woo Sung Kim, Jae Cheol Lee, Jin-Haeng Chung, Chang-Min Choi
Tuberc Respir Dis. 2013;75(3):95-103. Published online 2013 Sep 30 DOI: https://doi.org/10.4046/trd.2013.75.3.95
|
|
Citations to this article as recorded by
 Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes
Hao-Chun Chang, Kuan-Yu Chen, Yih-Leong Chang, Jin-Yuan Shih, Chong-Jen Yu
Journal of the Formosan Medical Association.2023; 122(8): 731. CrossRef Ultrastructural changes associated to the neuroendocrine transdifferentiation of the lung adenocarcinoma cell line A549
Irasema Mendieta, Maricela Rodríguez-Nieto, Rosa Elvira Nuñez-Anita, Jorge Luis Menchaca-Arredondo, Guadalupe García-Alcocer, Laura Cristina Berumen
Acta Histochemica.2021; 123(8): 151797. CrossRef Effect of A549 neuroendocrine differentiation on cytotoxic immune response
Irasema Mendieta, Rosa Elvira Nuñez-Anita, Gilberto Pérez-Sánchez, Lenin Pavón, Alfredo Rodríguez-Cruz, Guadalupe García-Alcocer, Laura Cristina Berumen
Endocrine Connections.2018; 7(5): 791. CrossRef Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors
Yi Shao, Dian-Sheng Zhong
International Journal of Clinical Oncology.2018; 23(2): 235. CrossRef Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report
Liying Fang, Jian He, Jingwen Xia, Liang Dong, Xiujuan Zhang, Yaqin Chai, Ying Li, Mengjie Niu, Tianxing Hang, Shengqing Li
Oncology Letters.2017; 14(1): 593. CrossRef Transformation to Small Cell Lung Cancer as an Acquired Resistance Mechanism in EGFR-mutant Lung Adenocarcinoma: A Case Report of Complete Response to Etoposide and Cisplatin
Ki-Eun Hwang, Jae-Wan Jung, Su-Jin Oh, Mi-Jeong Park, Young-Jun Shon, Keum-Ha Choi, Eun-Taik Jeong, Hak-Ryul Kim
Tumori Journal.2015; 101(3): e96. CrossRef Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor
Mariko Kogo, Ryoko Shimizu, Keiichiro Uehara, Yutaka Takahashi, Masaki Kokubo, Yukihiro Imai, Keisuke Tomii
Lung Cancer.2015; 90(2): 364. CrossRef Histological transformation from non‐small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor‐tyrosine kinase inhibitor
Woo‐Jin Kim, Sunmin Kim, Hayoung Choi, Jinsun Chang, Hong‐Joon Shin, Cheol‐Kyu Park, In‐Jae Oh, Kyu‐Sik Kim, Young‐Chul Kim, Yoo‐Duk Choi
Thoracic Cancer.2015; 6(6): 800. CrossRef An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib
Taeho Kwon, Jin Kyung Rho, Jae Cheol Lee, Young-Ho Park, Hye-Jun Shin, Sunwha Cho, Yong-Kook Kang, Bo-Yeon Kim, Do-Young Yoon, Dae-Yeul Yu
Experimental & Molecular Medicine.2015; 47(5): e165. CrossRef Targeting thioredoxin-1 with siRNA exacerbates oxidative stress injury after cerebral ischemia/reperfusion in rats
L. Li, K. Zhu, Y. Liu, X. Wu, J. Wu, Y. Zhao, J. Zhao
Neuroscience.2015; 284: 815. CrossRef
|